Haemonetics (HAE)
(Delayed Data from NYSE)
$74.77 USD
+0.73 (0.99%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $74.81 +0.04 (0.05%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth D Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Haemonetics Corporation has a market cap of $3.56B, which represents its share price of $74.04 multiplied by its outstanding shares number of 48.04M. As a mid-cap company, HAE's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
HAE 74.77 +0.73(0.99%)
Will HAE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HAE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HAE
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
Boston Scientific (BSX) Q2 Earnings and Revenues Surpass Estimates
HAE: What are Zacks experts saying now?
Zacks Private Portfolio Services
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Other News for HAE
XPH: Healthcare Dashboard For July
Haemonetics (HAE) Stock Maintains Outperform Rating by Barrington Research | HAE Stock News
Haemonetics (HAE) Receives Significant Upgrade from Citigroup | HAE Stock News
Haemonetics (HAE) Receives Upgrade as Outlook Improves | HAE Stock News
Haemonetics just upgraded at Citi, here's why